A phase 3, randomized, double-blind trial to evaluate the safety of a 20-valent pneumococcal conjugate vaccine in healthy infants at investigator sites in the United States and potentially other countries to be determined. This study is part of the Phase 3 clinical development program to support the use of 20vPnC in the pediatric population. The purpose of this study is to describe the safety of 20vPnC.